



AN ISO 9001 & A WHO GMP CERTIFIED COMPANY



To,

Date: 12.08.2016

BSE Limited
P. J. Towers, Dalal Street
Mumbai - 400 001

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 12.08.2016.
Ref: Scrip Code 539287



With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Ortin Laboratories Limited held on Friday, 12.08.2016 at 4.00 p.m., the following were duly considered and approved:

1. Un-audited financial results for the quarter ended 30.06.2016
2. Limited Review Report for the quarter ended 30.06.2016
3. 29th Annual General Meeting of the Company will be held on 30th September, 2016
4. Book closure for the purpose of Annual General Meeting will be from 24.09.2016 to 30.09.2016 (both days inclusive).
5. Appointment of Secretarial Auditors for the year 2016-17.

This is for the information and records of the Exchange, please.


Thanking you.

Yours faithfully,
For Ortin Laboratories Limited

S. Murali Krishna Murthy
Managing Director
DIN: 00540632

ORTIN LABORATORIES LIMITED					
H.NO. 1-2-593/29, STREET NO.4, GAGANMAHAL COLONY,DOMALGUDA,HYDERABAD-500029.					
STATEMENT FOR UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2016					
S. No	Particulars	(Rs. In Lakhs)			
		Three months ended	Preceding Three months ended	Corresponding Three months ended	Previous Year ended
		30.06.2016	31.03.2016	30.06.2015	31.03.2016
		Un-audited	Audited	Un-audited	Audited
1	Income from operations				
	(a) Net sales/income from operations (Net of excise duty)	648.13	1721.68	699.83	3976.93
	(b) Other operating income	578.22	693.41	528.35	2317.53
	Total income from operations (net)	1226.35	2415.09	1228.18	6294.47
2	Expenses				
	(a) Cost of materials consumed	603.98	2243.04	714.53	4507.64
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	93.42	-399.22	22.94	-375.04
	(d) Employee benefits expense	72.11	81.77	63.26	283.28
	(e) Depreciation and amortisation expense	41.77	40.86	40.52	164.74
	(f) Other expenses(Any item exceeding 10% of total expenses relating to continuing operations to be shown separately)(includes rates and taxes)	299.19	431.14	251.33	1289.60
	Total expenses	1110.46	2397.58	1092.58	5870.23
3	Profit / (Loss) from operations before other income, finance costs and exceptional items(1-2)	115.88	17.51	135.60	424.24
4	Other income	2.90	38.81	5.84	57.43
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	118.78	56.32	141.44	481.67
6	Finance costs	75.75	94.04	66.90	342.13
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	43.04	-37.73	74.54	139.54
8	Exceptional items	0.00	-0.82	0.00	0.05
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	43.04	-38.55	74.54	139.59
10	Tax expense	(46.25)	3.84	25.24	56.20
11	Net profit or loss from ordinary activities after tax(9+/-10)	89.29	-42.39	49.30	83.38
12	Extraordinary items (net of tax expense Rs.)	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11 + 12)	89.29	-42.39	49.30	83.38
14	Share of profit / (loss) of associates*	0.00	0.00	0.00	0.00
15	Minority interest *	0.00	0.00	0.00	0.00
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	89.29	-42.39	49.30	83.38
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	1694.04	1694.04	1694.04	1694.04
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	633.21	633.21	549.83	633.21
19.i.	Earnings per share (before extraordinary items) (of Rs.10/- each) (not annualised):				
	(a) Basic	0.53	-0.25	0.29	0.49
	(b) Diluted	0.53	-0.25	0.29	0.49
19.ii.	Earnings per share (after extraordinary items) (of Rs.10/- each) (not annualised):				
	(a) Basic	0.53	-0.25	0.29	0.49
	(b) Diluted	0.53	-0.25	0.29	0.49



Part II

ORTIN LABORATORIES LIMITED					
STATEMENT FOR UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2015					
S. No	Particulars	Three months ended	Preceeding Three months ended	CorrespondingT hree months ended	Previous Year ended
		30.06.2016	31-03-2016	30.06.2015	31.03.2016
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	i. Number of shares	11001052	11001052	10252259	11001052
	ii. Percentage of Shareholding	64.94%	64.94%	60.52%	64.94%
2	Promoters and Promoter Group Shareholding **				
	a) Pledged / Encumbered				
	i. Number of shares	0	0	0	0
	ii. Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0	0	0	0
	iii. Percentage of shares (as a % of the total share capital of the company)	0	0	0	0
	b) Non - encumbered				
	i. Number of shares	5939348	5939348	6688141	5939348
	ii. Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
	iii. Percentage of shares (as a % of the total share capital of the company)	35.06%	35.06%	39.48%	35.06%

Particulars	Three months ended 30.06.2016
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	0
Received during the quarter	0
Disposed of during the quarter	0
Remaining unresolved at the end of the quarter	0

NOTE: 1) The above results have been taken on record by the Board of directors at their meeting held on 12/08/2016

PLACE: HYDERABAD,
DATE: 12-08-2016

For ORTIN LABORATORIES LIMITED

S. MURALI KRISHNA MURTHY
MANAGING DIRECTOR





**Limited Review Report on Standalone Financial Results Pursuant to
Clause 33 of Listing Agreement**

Review Report to the Board of Directors of **ORTIN LABORTORIES LIMITED**

We have reviewed Part I - Unaudited Financial Results for the Quarter Ended 30/06/2016 of the accompanying Statement of Unaudited Financial Results ("Part I of the Statement") of **ORTIN LABORTORIES LIMITED**, which has been approved by the Board of Directors/ Committee of Board of Directors. The Statement has been prepared by the Company pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 which has been initialed by us for identification process.

Management is responsible for the preparation and presentation of the said Part I of the Statement in accordance with applicable Accounting Standards and other recognised accounting practices and policies. Our responsibility is to express a conclusion on the said Part I of the Statement based on our review.

Scope of Review

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the said Part I of the Statement is not prepared, in all material respects, in accordance with applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Clause 33 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 12/08/2016



For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS


B. V. RAMANA REDDY
M. No. 026967 Partner